Grand Pharmaceutical Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Grand Pharmaceutical Group hat ein Gesamteigenkapital von HK$15.3B und eine Gesamtverschuldung von HK$3.3B, wodurch sich der Verschuldungsgrad auf 21.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen HK$22.5B bzw. HK$7.2B. Grand Pharmaceutical Group Das EBIT des Unternehmens beträgt HK$2.9B, so dass der Zinsdeckungsgrad 14.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von HK$3.3B.

Wichtige Informationen

21.7%

Verhältnis von Schulden zu Eigenkapital

HK$3.31b

Verschuldung

Zinsdeckungsgrad	14.5x
Bargeld	HK$3.32b
Eigenkapital	HK$15.27b
Gesamtverbindlichkeiten	HK$7.24b
Gesamtvermögen	HK$22.52b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Recent updates

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Oct 20

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Sep 26

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Jun 04

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

May 05

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Nov 21

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Sep 05

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Aug 16

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Jul 28

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

May 29

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Apr 08

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Mar 22

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12

We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt

Apr 26

Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)

Apr 08

Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching

Mar 24

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 512Die kurzfristigen Aktiva des Unternehmens (HK$7.0B) übersteigen seine kurzfristigen Passiva (HK$5.7B).

Langfristige Verbindlichkeiten: 512Die kurzfristigen Vermögenswerte des Unternehmens (HK$7.0B) übersteigen seine langfristigen Verbindlichkeiten (HK$1.5B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 512 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 512 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 34.6% auf 21.7% zurückgegangen.

Schuldendeckung: 512Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (73.3%).

Zinsdeckung: Die Zinszahlungen für die Schulden von 512 sind durch das EBIT gut gedeckt (14.5x coverage).

Grand Pharmaceutical Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Recent updates

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Investor sentiment improved over the past week

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Executive Director recently bought HK$535k worth of stock

Upcoming dividend of HK$0.11 per share

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020)

Less than half of directors are independent

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 21% undervalued after recent price drop

Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration